What's keeping cancer patients from precision medicine?

5 July 2016
dr-alan-marks-big

In our weekly expert view piece, Dr Alan Marks, chairman of the Alliance for Patient Access, examines challenges faced by cancer patients in accessing precision medicine.

When former president Jimmy Carter announced at age 91 that breakthrough cancer drugs had eliminated his Stage IV melanoma, the hopes of patients and oncologists across the country soared.

Precision medicine is not just providing new treatment options; it is turning cancer care on its head. No longer do oncologists interpret certain diagnoses as near-certain death sentences.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical